According to the latest report by IMARC Group, titled "Global Liquid Biopsy Market Size, Share, Industry Trends, Growth, Opportunity and Forecast 2022-2027", The global liquid biopsy market reached a value of US$ 1.49 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.7 Billion by 2027 exhibiting a CAGR of 15.70% during 2022-2027.
Liquid
biopsy is the non-invasive sampling and analysis of liquid state biological
tissue, enabling doctors to obtain information about diseases like cancer and
tumors. This technique can reflect the changes in gene expression profile and
provide a robust base for individualized therapy. It is used for monitoring and
diagnosing diseases through advanced procedures like human genome sequencing.
Liquid biopsy is a fast, convenient and reproducible sampling method that
facilitates the early screening of cancer, monitors progression, accesses
therapeutic response and clinical prognosis, and detects recurrent and
refractory tumors.
|
Report
Metric |
|
Historical:
2016-2021 |
|
Base Year:
2021 |
|
Forecast
Year: 2022-2027 |
Liquid Biopsy
Market Trends and Drivers:
Liquid
biopsy reduces the apprehension of patients regarding pain and provides a safe
and effective method of diagnosis. As a result, there has been increasing
demand for a non-invasive alternative, such as liquid biopsy, over tissue
biopsy that involves the painful extraction of diseased tissue, which is
fueling the market growth.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/liquid-biopsy-market/requestsample
In addition,
the rising prevalence of cancer due to environmental factors, tobacco
consumption, Hepatitis B and C, and lifestyle changes is also escalating the
demand for liquid biopsy. Besides this, liquid biopsy is also widely adopted as
this technique detects epidermal growth factor receptor (EGFR) gene mutation
among patients with non-small cell lung cancer (NSCLC).
Furthermore,
technological advancements and extensive investments in research and
development (R&D) activities to encourage the introduction of advanced
cancer solutions are anticipated to positively influence the market growth in
the upcoming years.
Note: We are
regularly tracking the direct effect of COVID-19 on the market, along with the
indirect influence of associated industries. These observations will be
integrated into the report.
Global Liquid
Biopsy Market 2022-2027 Analysis and Segmentation:
Competitive
Landscape:
The
competitive landscape of the market has been studied in the report with the detailed
profiles of the key players operating in the market.
ANGLE plc,
Biocept Inc., Bio-Rad Laboratories Inc, Epigenomics AG, Exact Sciences
Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc.,
MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V. and Thermo Fisher
Scientific Inc.
The report has segmented the market on the
basis of region, product and service, circulating biomarker, cancer type
and end user.
Breakup by Product
and Service:
· Kits
and Reagents
· Platforms
and Instruments
· Services
Breakup by
Circulating Biomarker:
· Circulating
Tumor Cells
· Extracellular
Vesicles
· Circulating
Tumor DNA
· Others
Breakup by Cancer
Type:
· Lung
Cancer
· Breast
Cancer
· Colorectal
Cancer
· Prostate
Cancer
· Liver
Cancer
· Others
Breakup by End User:
· Hospitals
and Laboratories
· Academic
and Research Centers
· Others
Breakup by Region:
Ask Analyst
for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/liquid-biopsy-market
If you want
latest primary and secondary data (2022-2027) with Cost Module, Business
Strategy, Distribution Channel, etc. Click request free sample report,
published report will be delivered to you in PDF format via email within 24 to
48 hours of receiving full payment.
Key
highlights of the report:
If you need
specific information that is not currently within the scope of the report, we
can provide it to you as a part of the customization.
About Us:
IMARC Group
is a leading market research company that offers management strategy and market
research worldwide. We partner with clients in all sectors and regions to
identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s
information products include major market, scientific, economic and
technological developments for business leaders in pharmaceutical, industrial,
and high technology organizations. Market forecasts and industry analysis for
biotechnology, advanced materials, pharmaceuticals, food and beverage, travel
and tourism, nanotechnology and novel processing methods are at the top of the
company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia:
+91-120-433-0800, +91-120-433-0800